Organization Overview
Alternative names
loncastuximab (Zynlonta) (2021 NDA)
Burkitt Lymphoma (Phase 1)
Carcinoma (Phase 1)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Fallopian Tube Neoplasms (Phase 1)
Hodgkin Disease (Phase 2)
Leukemia (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)
Leukemia, Lymphoid (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 3)
Lymphoma, Follicular (Phase 1)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Mantle-Cell (Phase 1)
Lymphoma, Non-Hodgkin (Phase 1)
Lymphoma, T-Cell (Phase 1)
Lymphoma, T-Cell, Peripheral (Phase 1)
Myelodysplastic Syndromes (Phase 2)
Myeloproliferative Disorders (Phase 2)
Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 1)
Philadelphia Chromosome (Phase 2)
Preleukemia (Phase 2)
Triple Negative Breast Neoplasms (Phase 1)
Urinary Bladder Neoplasms (Phase 1)
Waldenstrom Macroglobulinemia (Phase 1)